Migraine Infusion Therapy: Eligibility Criteria & Key Considerations

Migraine Infusion Therapy: Eligibility Criteria & Key Considerations

IV infusion therapies (e.g., DHE, magnesium, valproate, newer CGRP antagonists) are options for refractory migraine. Determining candidacy requires thorough evaluation and shared decision-making with a headache specialist.

Critical Discussion Points with Your Provider

  • Medical history: Kidney, liver, cardiac disease, stroke, vascular risk factors.
  • Current medications: Interactions (e.g., triptans, ergots, SSRIs, antihypertensives).
  • Allergies: Especially to dyes, contrast, or drug components.
  • Pregnancy/breastfeeding status: Most infusions contraindicated or require careful risk-benefit analysis.
  • Lifestyle factors: Alcohol, smoking, caffeine—affect efficacy and vascular tone.
  • Insurance coverage: Pre-authorization, in-network facilities, out-of-pocket costs.
  • Specialist input: Neurologist/headache specialist assessment essential.
  • Clinical trial access: May offer novel agents (e.g., pituitary adenylate cyclase-activating polypeptide inhibitors).

Infusion Logistics

  • Setting: Hospital outpatient, infusion center, or home health (select therapies).
  • Duration: 30 min to several hours; may require series (e.g., DHE protocol).
  • Monitoring: Vitals, cardiac rhythm, side effects (nausea, hypotension, flushing).

Decision Framework

Infusion isn't first-line. It's considered when:

  • Oral/nasal abortives fail or contraindicated
  • Status migrainosus (>72 hr unremitting attack)
  • Medication overuse headache needing "bridge" therapy
  • Transitioning preventive regimens

Shared decision-making with a headache specialist optimizes outcomes and safety.

Migraine - Related Articles